What is he best known for?
The fields of study he is best known for:
His primary areas of study are Angiogenesis, Cell biology, Endothelial stem cell, Retinal and Retina.
His Angiogenesis study combines topics in areas such as Vascular endothelial growth factor A and Enos.
His studies deal with areas such as Inflammation, Immunology, Endothelium and Cell adhesion as well as Cell biology.
The Endothelial stem cell study combines topics in areas such as Histone H2A, Histone methyltransferase and Matrigel.
His Retinal research includes themes of Oxygen and Pathology.
His studies in Retina integrate themes in fields like Diabetic retinopathy, Endocrinology, Uridine diphosphate, Glycosylation and Internal medicine.
His most cited work include:
- Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species (376 citations)
- Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit (210 citations)
- Retinal light toxicity (159 citations)
What are the main themes of his work throughout his whole career to date?
Nader Sheibani focuses on Cell biology, Retinal, Angiogenesis, Internal medicine and Endothelial stem cell.
The various areas that he examines in his Cell biology study include Apoptosis, Cell adhesion and Matrigel.
His Retinal research integrates issues from Diabetic retinopathy, Retina and Pathology.
His Angiogenesis research incorporates themes from Vascular endothelial growth factor A and Endothelium.
His Internal medicine study incorporates themes from Diabetes mellitus and Endocrinology.
The study incorporates disciplines such as Molecular biology, Morphogenesis and Immunology in addition to Endothelial stem cell.
He most often published in these fields:
- Cell biology (27.06%)
- Retinal (23.34%)
- Angiogenesis (21.49%)
What were the highlights of his more recent work (between 2017-2021)?
- Retinal (23.34%)
- Cell biology (27.06%)
- Angiogenesis (21.49%)
In recent papers he was focusing on the following fields of study:
Nader Sheibani mainly focuses on Retinal, Cell biology, Angiogenesis, Choroidal neovascularization and Cancer research.
Nader Sheibani has researched Retinal in several fields, including Diabetic retinopathy, Oxidative stress, Inflammation, Apoptosis and Retina.
His Retina study incorporates themes from Hypoxia and Pathology.
His Cell biology research is multidisciplinary, incorporating elements of Pericyte, Cell adhesion and Cell type.
His studies in Angiogenesis integrate themes in fields like Endothelial stem cell, Vascular endothelial growth factor and Homeostasis.
His Macular degeneration research is multidisciplinary, relying on both Internal medicine and Endocrinology.
Between 2017 and 2021, his most popular works were:
- Vitamin D and regulation of vascular cell function (26 citations)
- Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing (17 citations)
- O-Linked β-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy. (11 citations)
In his most recent research, the most cited papers focused on:
Nader Sheibani spends much of his time researching Angiogenesis, Cancer research, Choroidal neovascularization, Retinal and Cell biology.
His Angiogenesis research incorporates themes from Endothelial stem cell and Inflammation.
His Endothelial stem cell study which covers Dental pulp stem cells that intersects with Molecular biology.
Nader Sheibani has included themes like Apoptosis, Retina, PEDF and Vascular endothelial growth factor in his Choroidal neovascularization study.
His Retinal research includes elements of Oxidative stress, Neurovascular bundle, Central nervous system, Cell adhesion and Extracellular matrix.
Nader Sheibani has researched Cell biology in several fields, including CD47 and Adherens junction.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
